<p>随着美国股市面临人工智能股票的压力并期待关键经济数据的发布，投资者密切关注这些因素如何影响更广泛的市场趋势。在如此波动的环境中，内部持股比例高的成长型公司往往脱颖而出，因为这表明了与企业关系最密切的人的信心，使它们成为在不确定性中寻求稳定的投资者的有趣选择。</p>
<h3>美国内部持股比例高的十大成长型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>盈利增长</strong></td>
</tr>
<tr>
<td>超微计算机 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.9%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17.3%</td>
<td>78.5%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.4%</td>
<td>52.7%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>27.1%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们内部持股比例高的快速成长美国公司筛选器中的 204 只股票的完整列表。</p>
<p>让我们深入探讨筛选器中的一些主要选择。</p>
<h2>Paysign (PAYS)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Paysign, Inc. 提供预付卡项目、患者负担能力解决方案、数字银行服务以及针对各个行业的综合支付处理，市值为 2.9503 亿美元。</p>
<p><strong>运营：</strong> Paysign 的收入主要来自其垂直整合的预付卡产品和处理服务提供商，收入为 7488 万美元。</p>
<p><strong>内部持股比例：</strong> 36.3%</p>
<p><strong>盈利增长预测：</strong> 每年 25.4%。</p>
<p>Paysign 的增长轨迹由预计每年增长 25.42% 的盈利所支撑，超过美国市场的 16.1%。尽管收入增长低于 20%，但仍高于市场平均水平 18.4%。最近的季度结果显示销售额和净收入同比显著改善，全年收入预计增长近 39%。公司的战略领导变动旨在增强其生命科学领域的存在，尽管内部交易活动仍然较少。</p>
<ul>
<li>通过阅读我们的分析师估计报告，深入了解 Paysign 的表现。</li>
<li>我们编制的估值报告表明，Paysign 当前的价格可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c8db4a8d-99e7-4237-9792-3a1d1f3383eb/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c8db4a8d-99e7-4237-9792-3a1d1f3383eb/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 PAYS 盈利和收入增长</p>
<h2>Amneal Pharmaceuticals (AMRX)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Amneal Pharmaceuticals, Inc. 是一家全球生物制药公司，开发、制造、营销和分销仿制药、注射剂、生物类似药和特种品牌药品，市值约为 39.2 亿美元。</p>
<p><strong>运营：</strong> 公司的收入部分包括 Avkare（7.0437 亿美元）、Specialty（4.8242 亿美元）和 Affordable Medicines（17.5 亿美元）。</p>
<p><strong>内部持股比例：</strong> 39.2%</p>
<p><strong>盈利增长预测：</strong> 每年 80.1%。</p>
<p>Amneal Pharmaceuticals 作为一家成长型公司，显示出潜力，内部持股比例显著，最近获得 FDA 对关键产品如肾上腺素注射剂和硫酸沙丁胺醇吸入气雾剂的批准，进一步丰富了其呼吸系统产品组合。尽管与同行相比交易价值良好，但预计公司在未来三年内盈利将显著增长，尽管收入增长预测落后于更广泛的市场。公司在复杂药物配方方面的战略举措凸显了其对创新的承诺。</p>
<ul>
<li>点击这里访问我们的完整增长分析报告，以了解 Amneal Pharmaceuticals 的动态。</li>
<li>我们的综合估值报告提出 Amneal Pharmaceuticals 的股价可能低于其财务状况所能证明的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/de8755ce-faf4-4170-8a24-89d67d81be0e/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/de8755ce-faf4-4170-8a24-89d67d81be0e/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 AMRX 盈利和收入增长</p>
<h2>Dingdong (Cayman) (DDL)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Dingdong (Cayman) Limited 作为一家电子商务公司在中国运营，市值约为 4.3933 亿美元。</p>
<p><strong>运营：</strong> 该公司主要通过其在线零售部门产生收入，报告为 240.2 亿人民币。</p>
<p><strong>内部持股比例：</strong> 28.6%</p>
<p><strong>盈利增长预测：</strong> 每年 25%。</p>
<p>Dingdong (Cayman) 展示了增长潜力，内部持股比例可观，与同行相比交易价值良好。尽管收入增长预测为每年 9.1%，落后于美国市场，但预计其盈利在未来三年将显著增长，年均增长 25%。最近的第三季度结果显示收入增加，但净收入和每股收益下降，反映出在扩张努力中维持盈利能力的挑战。</p>
<ul>
<li>点击以探索我们在 Dingdong (Cayman) 盈利增长报告中的详细发现。</li>
<li>我们的估值报告揭示了 Dingdong (Cayman) 的股票可能以折扣价交易的可能性。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a049d724-5af7-453a-a3bd-a419c44708f3/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a049d724-5af7-453a-a3bd-a419c44708f3/chart/ownership-breakdown"/></p>
<p>截至 2025 年 12 月的 DDL 持股结构</p>
<h2>利用机会</h2>
<ul>
<li>点击开始探索其余 201 只内部持股比例高的快速成长美国公司的信息。</li>
<li>寻找替代机会？我们发现 13 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</li>
</ul>
<p>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不意图作为财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</p>
<p>国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是类人型的，而是能够在 30 分钟内在任何地方提供 5G、ISR 和雷达的全自动塔。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

AMRX

<p>投资者在市场波动中密切关注内部持股比例高的成长型公司。值得注意的公司包括超级微型计算机（Super Micro Computer）、StubHub Holdings、SES AI、牛电科技（Niu Technologies）、Karman Holdings、Credo Technology、Corcept Therapeutics、Atour Lifestyle、Astera Labs 和 AppLovin。被特别提及的公司有 Paysign、Amneal Pharmaceuticals 和 Dingdong (Cayman)，它们均显示出显著的内部持股比例和良好的盈利增长预测。Simply Wall St 提供了详细的分析，但提醒其评论并非财务建议</p>

<p>As the U.S. stock market grapples with pressures on AI stocks and anticipates key economic data releases, investors are keenly observing how these factors influence broader market trends. In such a volatile environment, growth companies with high insider ownership often stand out as they suggest confidence from those closest to the business, making them intriguing prospects for investors seeking stability amid uncertainty.</p>
<div class="lb-trans"><p>随着美国股市面临人工智能股票的压力并期待关键经济数据的发布，投资者密切关注这些因素如何影响更广泛的市场趋势。在如此波动的环境中，内部持股比例高的成长型公司往往脱颖而出，因为这表明了与企业关系最密切的人的信心，使它们成为在不确定性中寻求稳定的投资者的有趣选择。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美国内部持股比例高的十大成长型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Super Micro Computer (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.9%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17.3%</td>
<td>78.5%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.4%</td>
<td>52.7%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>27.1%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>盈利增长</strong></td>
</tr>
<tr>
<td>超微计算机 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.9%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17.3%</td>
<td>78.5%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.4%</td>
<td>52.7%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>27.1%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 204 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们内部持股比例高的快速成长美国公司筛选器中的 204 只股票的完整列表。</p>
</div><p>Let's dive into some prime choices out of the screener.</p>
<div class="lb-trans"><p>让我们深入探讨筛选器中的一些主要选择。</p>
</div><h2>Paysign (PAYS)</h2>
<div class="lb-trans"><h2>Paysign (PAYS)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Paysign, Inc. offers prepaid card programs, patient affordability solutions, digital banking services, and integrated payment processing for various sectors with a market cap of $295.03 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Paysign, Inc. 提供预付卡项目、患者负担能力解决方案、数字银行服务以及针对各个行业的综合支付处理，市值为 2.9503 亿美元。</p>
</div><p><strong>Operations:</strong> Paysign's revenue primarily comes from its vertically integrated provider of prepaid card products and processing services, generating $74.88 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> Paysign 的收入主要来自其垂直整合的预付卡产品和处理服务提供商，收入为 7488 万美元。</p>
</div><p><strong>Insider Ownership:</strong> 36.3%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 36.3%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 25.4% p.a.</p>
<div class="lb-trans"><p><strong>盈利增长预测：</strong> 每年 25.4%。</p>
</div><p>Paysign's growth trajectory is underscored by a forecasted earnings increase of 25.42% per year, outpacing the US market's 16.1%. Despite revenue growth being slower than 20%, it surpasses the market average at 18.4%. Recent quarterly results show significant year-over-year improvements in sales and net income, with full-year revenues projected to grow by nearly 39%. The company's strategic leadership changes aim to enhance its life sciences sector presence, though insider trading activity remains minimal.</p>
<div class="lb-trans"><p>Paysign 的增长轨迹由预计每年增长 25.42% 的盈利所支撑，超过美国市场的 16.1%。尽管收入增长低于 20%，但仍高于市场平均水平 18.4%。最近的季度结果显示销售额和净收入同比显著改善，全年收入预计增长近 39%。公司的战略领导变动旨在增强其生命科学领域的存在，尽管内部交易活动仍然较少。</p>
</div><ul>
<li>Get an in-depth perspective on Paysign's performance by reading our analyst estimates report here.</li>
<li>The valuation report we've compiled suggests that Paysign's current price could be inflated.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的分析师估计报告，深入了解 Paysign 的表现。</li>
<li>我们编制的估值报告表明，Paysign 当前的价格可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c8db4a8d-99e7-4237-9792-3a1d1f3383eb/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/c8db4a8d-99e7-4237-9792-3a1d1f3383eb/chart/earnings-and-revenue-growth"/></p>
<p>PAYS Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 PAYS 盈利和收入增长</p>
</div><h2>Amneal Pharmaceuticals (AMRX)</h2>
<div class="lb-trans"><h2>Amneal Pharmaceuticals (AMRX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide with a market cap of approximately $3.92 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Amneal Pharmaceuticals, Inc. 是一家全球生物制药公司，开发、制造、营销和分销仿制药、注射剂、生物类似药和特种品牌药品，市值约为 39.2 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue segments include Avkare at $704.37 million, Specialty at $482.42 million, and Affordable Medicines at $1.75 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入部分包括 Avkare（7.0437 亿美元）、Specialty（4.8242 亿美元）和 Affordable Medicines（17.5 亿美元）。</p>
</div><p><strong>Insider Ownership:</strong> 39.2%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 39.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 80.1% p.a.</p>
<div class="lb-trans"><p><strong>盈利增长预测：</strong> 每年 80.1%。</p>
</div><p>Amneal Pharmaceuticals shows potential as a growth company with significant insider ownership, highlighted by its recent FDA approvals for key products like epinephrine injections and albuterol sulfate inhalation aerosol, adding to its expanding respiratory portfolio. While trading at a good value compared to peers, the company's earnings are expected to grow significantly over the next three years, despite revenue growth forecasts lagging behind the broader market. The company's strategic moves in complex drug formulations underscore its commitment to innovation.</p>
<div class="lb-trans"><p>Amneal Pharmaceuticals 作为一家成长型公司，显示出潜力，内部持股比例显著，最近获得 FDA 对关键产品如肾上腺素注射剂和硫酸沙丁胺醇吸入气雾剂的批准，进一步丰富了其呼吸系统产品组合。尽管与同行相比交易价值良好，但预计公司在未来三年内盈利将显著增长，尽管收入增长预测落后于更广泛的市场。公司在复杂药物配方方面的战略举措凸显了其对创新的承诺。</p>
</div><ul>
<li>Click here and access our complete growth analysis report to understand the dynamics of Amneal Pharmaceuticals.</li>
<li>Our comprehensive valuation report raises the possibility that Amneal Pharmaceuticals is priced lower than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整增长分析报告，以了解 Amneal Pharmaceuticals 的动态。</li>
<li>我们的综合估值报告提出 Amneal Pharmaceuticals 的股价可能低于其财务状况所能证明的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/de8755ce-faf4-4170-8a24-89d67d81be0e/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/de8755ce-faf4-4170-8a24-89d67d81be0e/chart/earnings-and-revenue-growth"/></p>
<p>AMRX Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 AMRX 盈利和收入增长</p>
</div><h2>Dingdong (Cayman) (DDL)</h2>
<div class="lb-trans"><h2>Dingdong (Cayman) (DDL)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Dingdong (Cayman) Limited operates as an e-commerce company in China with a market cap of approximately $439.33 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Dingdong (Cayman) Limited 作为一家电子商务公司在中国运营，市值约为 4.3933 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily through its online retail segment, which reported CN¥24.02 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其在线零售部门产生收入，报告为 240.2 亿人民币。</p>
</div><p><strong>Insider Ownership:</strong> 28.6%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 28.6%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 25% p.a.</p>
<div class="lb-trans"><p><strong>盈利增长预测：</strong> 每年 25%。</p>
</div><p>Dingdong (Cayman) demonstrates growth potential with substantial insider ownership, trading at a good value compared to peers. Despite revenue growth forecasts of 9.1% per year lagging behind the US market, its earnings are expected to grow significantly at 25% annually over the next three years. Recent Q3 results showed increased revenue but decreased net income and earnings per share, reflecting challenges in maintaining profitability amidst expansion efforts.</p>
<div class="lb-trans"><p>Dingdong (Cayman) 展示了增长潜力，内部持股比例可观，与同行相比交易价值良好。尽管收入增长预测为每年 9.1%，落后于美国市场，但预计其盈利在未来三年将显著增长，年均增长 25%。最近的第三季度结果显示收入增加，但净收入和每股收益下降，反映出在扩张努力中维持盈利能力的挑战。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Dingdong (Cayman)'s earnings growth report.</li>
<li>Our valuation report unveils the possibility Dingdong (Cayman)'s shares may be trading at a discount.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击以探索我们在 Dingdong (Cayman) 盈利增长报告中的详细发现。</li>
<li>我们的估值报告揭示了 Dingdong (Cayman) 的股票可能以折扣价交易的可能性。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a049d724-5af7-453a-a3bd-a419c44708f3/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/a049d724-5af7-453a-a3bd-a419c44708f3/chart/ownership-breakdown"/></p>
<p>DDL Ownership Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 DDL 持股结构</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用机会</h2>
</div><ul>
<li>Click through to start exploring the rest of the 201 Fast Growing US Companies With High Insider Ownership now.</li>
<li>Looking For Alternative Opportunities? We've found 13 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击开始探索其余 201 只内部持股比例高的快速成长美国公司的信息。</li>
<li>寻找替代机会？我们发现 13 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不意图作为财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的，而是能够在 30 分钟内在任何地方提供 5G、ISR 和雷达的全自动塔。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

三家受到内部人士青睐的成长型公司值得关注